Loading clinical trials...
Loading clinical trials...
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab in subjects wi...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
CONTACT
650-405-8440onkoras-101ct.gov@bridgebiooncology.comLead Sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT05967689 · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
NCT07668037 · Non-Small Cell Carcinoma of Lung, Immunotherapy, and more
NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more
NCT06529822 · Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, and more
NCT07164170 · Non-Small Cell Lung Cancer
O'Neal Comprehensive Cancer Center at UAB
Birmingham, Alabama
University of California - San Diego Moores Cancer Center
La Jolla, California
University of California San Francisco
San Francisco, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions